Polly Clayden

CROI 2019: Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.  

Read More →

CROI 2019: Dolutegravir can be given with 3HP to prevent TB without dose adjustment

Dolutegravir (DTG) can be given with short-course TB preventive therapy of 12 once-weekly rifapentine/isoniazid (3HP) without dose adjustment, according to data from the DOLPHIN trial, presented at CROI 2019. [1]

Read More →

Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin

Plasma concentrations of tenofovir alafenamide AUC were decreased by 55% and intracellular tenofovir-diphosphate concentrations by 36% when given with rifampicin. But intracellular concentrations were still 76% higher than those with standard dose tenofovir disoproxil fumarate.

Read More →

Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin

Twice-daily tenofovir alafenamide (TAF) plus rifampicin provided similar exposures to once-daily TAF in pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.

Read More →

Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

Twice daily dolutegravir in combination with rifampicin was well tolerated and produced good outcomes in a small retrospective study presented at HIV Drug Therapy Glasgow 2016. [1]  

Read More →

Universal treatment of multidrug-resistant TB is possible within current budgets with generic production

Generic production could make novel multidrug-resistant tuberculosis (MDR-TB) regimens available for US $53–507 per treatment course according to data presented at TB2016.

Read More →

Shortened nine-month MDR-TB regimen works well in children and adolescents

The nine-month Bangladesh regimen for treatment of multidrug-resistant tuberculosis (MDR-TB) was successful in 83% of children and adolescents in an observational trial conducted in francophone Africa, presented at TB2016. [1]

Read More →

Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB

Levofloxacin was safe and well tolerated in children with and without HIV in long-term use. The data provide additional support for its inclusion in paediatric TB treatment and prevention regimens. [1]

Read More →

The REALITY trial: cotrimoxazole/isoniazid/pyridoxine tablets are bioequivalent to individual products and are acceptable to participants

Cotrimoxazole/isoniazid/pyridoxine (CTX/INH/B6) scored fixed dose combination (FDC) tablets are bioequivalent to individual drugs and are acceptable, reduce pill burden and could improve adherence for adults and children, according to results from the REALITY trial presented at the 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union).

Read More →

Pharmacokinetics of old and new TB drugs for children

Several presentations at the 46th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease showed pharmacokinetic (PK) data for anti-tuberculosis (TB) drugs in children.

Read More →

Page 1 of 2 · Total posts: 10

1 2 Last→